Bellevue Group AG Grows Position in DexCom, Inc. (NASDAQ:DXCM)

Bellevue Group AG raised its stake in DexCom, Inc. (NASDAQ:DXCM) by 33.5% during the first quarter, HoldingsChannel reports. The fund owned 1,221,197 shares of the medical device company’s stock after buying an additional 306,604 shares during the period. DexCom comprises approximately 2.6% of Bellevue Group AG’s holdings, making the stock its 9th largest position. Bellevue Group AG’s holdings in DexCom were worth $169,380,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Team Hewins LLC grew its position in DexCom by 3.4% during the 1st quarter. Team Hewins LLC now owns 2,555 shares of the medical device company’s stock valued at $354,000 after purchasing an additional 83 shares during the last quarter. Bleakley Financial Group LLC increased its position in shares of DexCom by 1.3% during the first quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock valued at $951,000 after acquiring an additional 87 shares in the last quarter. D Orazio & Associates Inc. increased its position in shares of DexCom by 0.8% during the fourth quarter. D Orazio & Associates Inc. now owns 12,366 shares of the medical device company’s stock valued at $1,534,000 after acquiring an additional 93 shares in the last quarter. Gulf International Bank UK Ltd raised its holdings in DexCom by 0.3% in the 1st quarter. Gulf International Bank UK Ltd now owns 32,075 shares of the medical device company’s stock worth $4,448,000 after acquiring an additional 93 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its position in DexCom by 10.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the medical device company’s stock valued at $133,000 after acquiring an additional 98 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on DXCM shares. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a research note on Monday, June 10th. Redburn Atlantic began coverage on DexCom in a research report on Thursday, May 30th. They issued a “neutral” rating and a $130.00 target price for the company. Oppenheimer dropped their price target on shares of DexCom from $150.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday. Raymond James boosted their price objective on shares of DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a report on Friday, April 26th. Finally, BTIG Research lowered their price objective on shares of DexCom from $156.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $113.06.

Insider Buying and Selling at DexCom

In other news, EVP Michael Jon Brown sold 629 shares of the firm’s stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $126.25, for a total transaction of $79,411.25. Following the sale, the executive vice president now directly owns 68,212 shares in the company, valued at approximately $8,611,765. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Michael Jon Brown sold 629 shares of the business’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $126.25, for a total value of $79,411.25. Following the transaction, the executive vice president now directly owns 68,212 shares of the company’s stock, valued at approximately $8,611,765. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Jereme M. Sylvain sold 745 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $115.05, for a total value of $85,712.25. Following the completion of the transaction, the chief financial officer now owns 84,948 shares of the company’s stock, valued at $9,773,267.40. The disclosure for this sale can be found here. Insiders have sold 4,112 shares of company stock valued at $480,861 over the last 90 days. 0.30% of the stock is currently owned by corporate insiders.

DexCom Stock Performance

NASDAQ DXCM traded down $43.85 on Friday, hitting $64.00. 53,914,127 shares of the company traded hands, compared to its average volume of 2,657,874. The business’s 50 day moving average price is $115.28 and its 200-day moving average price is $123.76. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The company has a current ratio of 2.90, a quick ratio of 2.53 and a debt-to-equity ratio of 1.08. The company has a market capitalization of $25.45 billion, a price-to-earnings ratio of 41.29, a P/E/G ratio of 1.57 and a beta of 1.16.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $1.04 billion. DexCom had a return on equity of 32.27% and a net margin of 16.95%. The business’s quarterly revenue was up 15.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.34 EPS. Equities analysts expect that DexCom, Inc. will post 1.76 earnings per share for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.